These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23090561)

  • 41. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
    Bird ST; Delaney JA; Etminan M; Brophy JM; Hartzema AG
    J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined hormonal contraceptives and the risk of venous and arterial thromboembolism and cardiovascular death: misuse of automated databases.
    Shapiro S
    J Fam Plann Reprod Health Care; 2013 Apr; 39(2):89-96. PubMed ID: 23493593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J; Möhner S; Heinemann K
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral contraceptives and venous thromboembolism: old questions revisited.
    Dinger J
    J Fam Plann Reprod Health Care; 2009 Oct; 35(4):211-3. PubMed ID: 19849911
    [No Abstract]   [Full Text] [Related]  

  • 45. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ; 2015 May; 350():h2135. PubMed ID: 26013557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral contraceptives and venous thromboembolism: pill scares and public health.
    Reid RL
    J Obstet Gynaecol Can; 2011 Nov; 33(11):1150-5. PubMed ID: 22082790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Oral contraceptive pill and thrombotic risk: epidemiological studies].
    Fruzzetti F; Perini D; Spirito N; Manca R
    Minerva Ginecol; 2012 Dec; 64(6):539-49. PubMed ID: 23232538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hormonal contraceptives and venous thromboembolism: an epidemiological update.
    Plu-Bureau G; Maitrot-Mantelet L; Hugon-Rodin J; Canonico M
    Best Pract Res Clin Endocrinol Metab; 2013 Feb; 27(1):25-34. PubMed ID: 23384743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of blood clots higher for oral contraceptives with certain progestins.
    Voelker R
    JAMA; 2011 Nov; 306(20):2206. PubMed ID: 22110099
    [No Abstract]   [Full Text] [Related]  

  • 50. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of oral contraceptives for teenagers. ACOG Committee opinion: Committee on Adolescent Health Care number 90--February 1991.
    Int J Gynaecol Obstet; 1992 Apr; 37(4):309-12. PubMed ID: 1350552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pregnancy is more dangerous than the pill: A critical analysis of professional responses to the Yaz/Yasmin controversy.
    Geampana A
    Soc Sci Med; 2016 Oct; 166():9-16. PubMed ID: 27522113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controversies in postpartum contraception: when is it safe to start oral contraceptives after childbirth?
    Jackson E
    Thromb Res; 2011 Feb; 127 Suppl 3():S35-9. PubMed ID: 21262436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The risks of oral contraceptive pills.
    Pymar HC; Creinin MD
    Semin Reprod Med; 2001 Dec; 19(4):305-12. PubMed ID: 11727172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
    Price DT; Ridker PM
    Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias.
    Realini JP; Encarnacion CE; Chintapalli KN; Rees CR
    J Am Board Fam Pract; 1997; 10(5):315-21. PubMed ID: 9297655
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
    Lidegaard O
    BMJ; 1993 Apr; 306(6883):956-63. PubMed ID: 8490470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?
    Drife J
    Drug Saf; 2002; 25(13):893-902. PubMed ID: 12381211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(26):878-83. PubMed ID: 21734635
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidemiology of hormonal contraceptives-related venous thromboembolism.
    Hugon-Rodin J; Gompel A; Plu-Bureau G
    Eur J Endocrinol; 2014 Dec; 171(6):R221-30. PubMed ID: 25012200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.